PDF(Pubmed)
Abstract：
There is minimal knowledge regarding the durability of neutralization capacity and level of binding antibody generated against the highly transmissible circulating Omicron subvariants following SARS-CoV-2 infection in children with acute COVID-19 and those diagnosed with multisystem inflammatory syndrome in children (MIS-C) in the absence of vaccination. In this study, SARS-CoV-2 neutralization titers against the ancestral strain (WA1) and Omicron sublineages were evaluated in unvaccinated children admitted for COVID-19 (n = 32) and MIS-C (n = 32) at the time of hospitalization (baseline) and at six to eight weeks post-discharge (follow-up) between 1 April 2020, and 1 September 2022. In addition, antibody binding to the spike receptor binding domain (RBD) from WA1, BA.1, BA.2.75, and BA.4/BA.5 was determined using surface plasmon resonance (SPR). At baseline, the children with MIS-C demonstrated two-fold to three-fold higher binding and neutralizing antibodies against ancestral WA1 compared to those with COVID-19. Importantly, in children with COVID-19, the virus neutralization titers against the Omicron subvariants at six to eight weeks post-discharge reached the same level as those with MIS-C had at baseline but were higher than titers at 6-8 weeks post-discharge for MIS-C cases. Cross-neutralization capacity against recently emerged Omicron BQ.1, BQ.1.1, and XBB.1 variants was very low in children with either COVID-19 or MIS-C at all time points. These findings about post-infection immunity in children with either COVID-19 or MIS-C suggest the need for vaccinations in children with prior COVID-19 or MIS-C to provide effective protection from emerging and circulating SARS-CoV-2 variants.
摘要：
关于急性COVID-19儿童和被诊断患有多系统炎症综合征（MIS-C）的儿童在SARS-CoV-2感染后针对高度传染性的循环Omicron亚变体产生的中和能力的持久性和结合抗体水平的知识很少。在这项研究中,在2020年4月1日至2022年9月1日期间，在住院时（基线）和出院后6至8周（随访），对未接种COVID-19（n=32）和MIS-C（n=32）的未接种疫苗的儿童评估了SARS-CoV-2对祖先菌株（WA1）和Omicron亚谱系的中和滴度。此外,使用表面等离子体共振（SPR）确定抗体与来自WA1，BA.1，BA.2.75和BA.4/BA.5的刺突受体结合域（RBD）的结合。在基线,与患有COVID-19的儿童相比，患有MIS-C的儿童对祖先WA1的结合和中和抗体高两倍至三倍。重要的是,在患有COVID-19的儿童中,出院后6~8周时针对Omicron亚变体的病毒中和滴度达到与MIS-C患儿基线时相同的水平,但高于MIS-C患儿出院后6~8周时的滴度.在所有时间点，患有COVID-19或MIS-C的儿童对最近出现的OmicronBQ.1、BQ.1.1和XBB.1变体的交叉中和能力都非常低。这些关于患有COVID-19或MIS-C的儿童感染后免疫的发现表明，有必要在患有COVID-19或MIS-C的儿童中接种疫苗，以提供有效的保护，免受新出现和流行的SARS-CoV-2变体的影响。
